AndhraNews.net
Home » Features » Health » Crohns disease

Crohns disease


About Crohn's disease

Crohn's disease is an autoimmune disease.

A study showed that eating plantain and broccoli fibre could help prevent relapses of Crohns disease. Vitamin D, readily available in supplements or cod liver oil, can counter the effects of the disease.

A nutritional powder consumed by astronauts can be used for treating inflammatory bowel disease in children, say researchers.

Crohns disease in News

StockNewsNow.com Publishes New SNNLive Video Interview With BioLargo, Inc.
LOS ANGELES, CA--(Marketwired - December 23, 2015) - StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Dennis Calvert, President and CEO of BioLargo, Inc

StockNewsNow.com Publishes Q3 2015 Review SNNLive Video Interview With Immune Pharmaceuticals, Inc.
LOS ANGELES, CA--(Marketwired - November 02, 2015) - StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Dr. Daniel Teper, CEO of Immune Pharmaceuticals, Inc

Curb Energy Consumption
(Family Features) Water heaters are energy intensive appliances. In fact, they are the second largest energy user in the home, and as they age, they become less efficient, requiring even more energy.

Sinequa Selected by UCB to Reduce Time and Cost of Searching Clinical Trial Data
Sinequa, a leader in real-time Big Data search and analytics, today announced that UCB has selected the Sinequa Big Data Search & Analytics Platform to speed vital information discovery of its clinical trial file share

Stellar Biotechnologies Reports Fiscal Year-End 2015 Financial Results and Operational Highlights
Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (NASDAQ: SBOT) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), reported financial results for the year ended September 30, 2015.

IntelGenx and RedHill Biopharma Announce First European Marketing Approval of RIZAPORT(TM) for Migraines

Stellar Biotechnologies Issues Corporate Update
Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), today issued a corporate update from its President, Chief Executive Officer, and Chairman Frank Oakes.

Stevia Corp. Announces Real Hemp LLC's Collaboration With Internationally Recognized Designer and the Rubber Killer(R) Brand
Stevia Corp

Reduce Exposure to Tuberculosis With RxAir UV Light Air Purification
Healthcare professionals are concerned about recent increases in tuberculosis (TB) cases across the US because individuals with weakened immune systems, such as from diabetes, are highly susceptible to infections and complications

DirectRx Pharmacy Announces Specialty Pharmacy Accreditation From ACHC
DirectRx (www.DirectRx.com), an independent, specialty pharmacy based in Troy, Mich., today announced it has been awarded the Specialty Pharmacy (SRX) accreditation by the Accreditation Commission for Health Care (ACHC), a national organization developed by homecare and alternate-site healthcare industry providers. The announcement was made by Amanda Berishaj, PharmD, of DirectRx.

Stevia Corp. Reports on Budget Hemp's Better Than Expected Sales Numbers Following Launch of Online Store
Stevia Corp

Stevia Corp. Reports on Initial Sales Trends for Realhemp(TM) Branded Product Lines
Stevia Corp. (OTC PINK: STEV) ("Stevia Corp" or the "Company"), an international farm management company and healthcare company focused on the commercial development of products that support a healthy lifestyle, including stevia and hemp and their compounds, is pleased to provide an update on the initial success of its wholly-owned subsidiary Real Hemp LLC's Realhemp™ product lines.

Stevia Corp. Launches Its Bulk Hemp Products Online Store at www.BudgetHemp.com for Commercial Buyers
Stevia Corp. (OTC PINK: STEV) ("Stevia Corp" or the "Company"), an international farm management company and healthcare company focused on the commercial development of products that support a healthy lifestyle, including stevia and hemp and their compounds, is pleased to announce that its wholly-owned subsidiary Real Hemp LLC has launched its second online store at www.BudgetHemp

Stevia Corp. Launches Its Online Store at www.RealhempStore.com Featuring Realhemp(TM) Branded Food and Skincare Product Lines
Stevia Corp. (OTC PINK: STEV) ("Stevia Corp" or the "Company"), an international farm management company and healthcare company focused on the commercial development of products that support a healthy lifestyle, including stevia and hemp and their compounds is pleased to announce that its wholly-owned subsidiary Real Hemp LLC has launched its online store at www.RealhempStore

Stevia Corp. Provides Update on 10-K Filing
Stevia Corp. (OTC PINK: STEV) ("Stevia Corp" or the "Company"), an international farm management company and healthcare company focused on the commercial development of products that support a healthy lifestyle, including stevia and hemp and their compounds is providing an update for its pending 10-K filing.

Orgenesis Subsidiary MaSTherCell to Manufacture TxCell's Lead Product Ovasave for Multi-National Phase 2b Trial
Orgenesis Inc

Vista Partners Initiates Coverage on Immune Pharmaceuticals Inc. (NasdaqCM: IMNP); $6.00 Price Target
Vista Partners announced today that it has initiated coverage on Immune Pharmaceuticals Inc. (NASDAQ: IMNP); with a twelve-month price target of $6.00. Ross Silver, Principal Analyst at Vista Partners, stated, "Immune Pharmaceuticals Inc

Stevia Corp. Discusses Partnership Plans While Continuing to Implement a Broad Intellectual Property and Commercial Strategy Related to Cannabis and Industrial Hemp
Stevia Corp

Stevia Corp. Names Famed Cannabis Researcher and Former Indiana University Professor Paul Mahlberg to Its Advisory Panel
Stevia Corp. (OTCQB: STEV) ("Stevia Corp" or the "Company"), an international farm management company and healthcare company focused on the commercial development of products that support a healthy lifestyle, including stevia and hemp and their compounds is pleased to announce the addition of Dr. Paul Mahlberg to Stevia Corp.'s newly formed Advisory Panel.

GOT GUTS? Time to Get Your Bike Out and Get Your Guts in Gear -- The Ride for Crohn's and Colitis
PEEKSKILL, NY--(Marketwired - April 22, 2015) - Get Your Guts in Gear, The Ride for Crohn's and Colitis, (GYGIG), has opened registration for its 2015 Rides

CEO Dr. Daniel Teper of Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) to Be Interviewed Live on Clear Channel - iHeart Business Talk Radio - December 9, 2014
Immune Pharmaceuticals, Inc

Cellceutix Investigational New Drug (IND) Application Becomes Effective, Selects First Site for Phase 2 Clinical Trial of New Treatment for Oral Mucositis

Cytovance Biologics, Inc. and Selexys Pharmaceuticals, Corp. Announce Development and cGMP Manufacturing Agreement for SELK2 Drug Product
Cytovance Biologics, Inc., a leading full-service contract manufacturer ("CMO") of mammalian and microbial biologics, announces a development and manufacturing agreement with Selexys Pharmaceuticals, Corp., an Oklahoma City-based clinical stage biopharmaceutical company.

MediSwipe, Inc. Announces Approval of Charlotte's Web Legislation by Florida House and Senate as Company Seeks Top Candidacy for Participation in State Licenses
LOS ANGELES, CA--(Marketwired - May 05, 2014) - MediSwipe, Inc. (www.MediSwipe.com) (OTCQB: MWIP), a fully reporting company on the OTCQB, a leader in the Compassionate Care Industry which provides technology and business solutions, today announced that the Florida Senate passed the bill known as "Charlotte's Web" legislation on Friday after the House overwhelmingly passed it Thursday

HPC POS System Acquires Here We Grow Store
HPC POS System, Corp. ("HPC" or the "Company") (OTC Pink: HPCS) (PINKSHEETS: HPCS), a health company specializing in advances in supplements for health, and anti-aging, announced today that the Company has acquired Here We Grow Store, a national retailer of indoor gardening and horticulture equipment and growing supplies headquartered in Denver, Colorado

Genetic and Microbiome Discoveries Point the Way to New Treatments for IBD

Largest Microbiome Study on Newly Diagnosed Patients Gives Insight Into Crohn's Disease and Shows Antibiotic Treatment May Worsen Disease
NEW YORK, NY--(Marketwired - March 12, 2014) - An important new study funded by the Crohn's & Colitis Foundation of America (CCFA) and published in the March 12 issue of Cell Host & Microbe, reveals several important findings that identify the microbiome in early-onset Crohn's disease and highlight particular microbes that are increased or decreased in abundance in the disease

Plandai Biotechnology: A Natural Fit Into the Marijuana Industry
Plandaí Biotechnology (OTCQB: PLPL) has a strong executive team in place, a well thought out business plan, and now it's time for the company to make its products the star. These products include Plandaí's Phytofare™ botanical extracts such as its Green Tea Catechin Complex and the Limonoid Glycoside Complex, as well as a line of Diego Pellicer® medical cannabis products

Resolution Running 101
NEW YORK, NY--(Marketwired - February 13, 2014) - Is the Polar Vortex getting you down? Don't let it! Cold weather is no reason to lose motivation and give up on your 2014 fitness goal. This year, let the Crohn's & Colitis Foundation of America's Team Challenge provide the support and accountability that you need to reach your fitness goals in 2014. 

Face the Nation's Bob Schieffer to Serve as 2014 Take Steps Walk Honorary Chair
NEW YORK, NY--(Marketwired - February 06, 2014) -  The Crohn's & Colitis Foundation of America (CCFA) is delighted to announce that Emmy Award winning political commentator and TV host Bob Schieffer will serve as Honorary Chair for Take Steps in 2014. A patient himself, Mr. Schieffer understands the importance of raising funds and awareness for digestive diseases.

Team Challenge Gearing Up For Summer Season
NEW YORK, NY--(Marketwired - January 13, 2014) - The Crohn's & Colitis Foundation of America's endurance training and fundraising program, Team Challenge, is thrilled to unveil its upcoming race portfolio with 8 great endurance events scheduled this summer including:

Galapagos half year revenues up 21%
·       Group revenues €77.4 M compared to €64.5 M in H1 2012·       Group net loss reduced to €5.4 M, from €11.3 M last year·       Cash position of €136

Galapagos presents GLPG0634 at EULAR poster session
Posters now available online at www.glpg.comQ&A session with Galapagos CSO today at 15

TEVA AND ACTIVE BIOTECH REPORT POSITIVE RESULTS FROM PHASE IIa STUDY OF LAQUINIMOD IN ACTIVE LUPUS NEPHRITIS
· Laquinimodshowed additive effect in improving renal function when combined with thestandard of care treatment· Results provide rationale for further studies of laquinimodin active lupus nephritis to confirm the safety and efficacy profileobserved in this study

CCFA Partners Inititative Receives Funding From Patient-Centered Outcomes Research Institute
NEW YORK, NY--(Marketwired - December 20, 2013) - At a time when funding is increasingly difficult to secure, the Crohn's & Colitis Foundation of America's CCFA Partners Research Initiative has been approved for an award by the Patient-Centered Outcomes Research Institute (PCORI)

Conversant Bio Releases Immunology E-Book
Conversant Bio, a global leader in supplying the highest-quality human tissue and viable cell samples, today announced it is publishing a new e-book to provide researchers with a guide to autoimmune disorders. The e-book Researchers Guide to Immunology: From the Real World to the Lab, is available as a free download at http://www.conversantbio.com/researchers-guide-to-immunology-ebook.

Profile of Pediatric IBD: Initial Findings From CCFA Partners Kids & Teens

LifeSci Advisors Initiates Coverage of Immune Pharmaceuticals
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Immune Pharmaceuticals Inc. (NASDAQ OMX First North Premier: IMNP) (OTCQX: IMNP), a clinical stage biopharmaceutical company focused on developing antibody therapeutics for inflammatory diseases and cancer

Qu Biologics Granted Broad European Patent for Targeted Treatment of Multiple Cancers
Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to reboot the body's immune system to treat cancer and autoimmune disease, announced it has been granted a broad European patent covering the use of vaccines derived from bacterial components to stimulate a targeted immune response to a variety of common cancers.

TNI BioTech, Inc. Subsidiary Granted Certificate of Free Sale by Nicaraguan Minister of Health for Low Dose Naltrexone
TNI BioTech Inc (OTCQB: TNIB) today announced that the Nicaraguan Ministry of Health has granted a certificate of free sale to the company's wholly-owned subsidiary, TNI BioTech International Ltd., for TNI BioTech's Low Dose Naltrexone product (LDN) for the treatment of patients with autoimmune diseases HIV/AIDS, Crohn's Disease, Multiple Sclerosis and certain cancers.

Crohn's Disease & Ulcerative Colitis Costs the US in the Billions
NEW YORK, NY--(Marketwired - December 02, 2013) - The estimated direct cost for all patients with inflammatory bowel diseases (IBD) in the US is $1.84 billion

13.1 Miles 5 Years in a Row Raises $20M for Crohn's and Colitis Research
NEW YORK, NY--(Marketwired - November 12, 2013) - The Crohn's & Colitis Foundation of America's Team Challenge is thrilled to be celebrating its fifth anniversary as the official charity partner of the Rock 'n' Roll Las Vegas Marathon & Half Marathon taking place on Sunday November 17, 2013.

Plandai Enters Medical Marijuana Market
Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that in a move that could add meaningful value to the overall company, Plandaí Biotechnology, Inc. (OTCQB: PLPL) recently announced that it has formed a new wholly-owned subsidiary, Cannabis Biosciences, Inc

Plandai Biotechnology, Inc. to Enter Medical Marijuana Field With Phyto Cannabinoid Extract
Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that it has formed a new wholly-owned subsidiary, Cannabis Biosciences, Inc., in Delaware, for the purpose of developing and testing a new Phytofare™ botanical extract derived from cannabis.

David&Goliath Introduces the "Defiance Club"
David Angelo, Founder and Chief Creative Officer of creative agency David&Goliath (D&G), today announced the launch of the "Defiance Club," an agency initiative that allows employees to defy their personal challenges (a.k.a. Goliaths), no matter how big or small, with the financial and moral support of the agency to help them succeed.

Cellceutix Completes Acquisition of PolyMedix Assets, Immediately Plans Brilacidin(TM) Phase 2b Clinical Trial for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Phase 2 Clinical Trial for Oral Mucositis
Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical company, is pleased to provide shareholders an update regarding the Company's recent acquisition of the assets of PolyMedix

New Study on Colorectal Surgery Outlines Learning Curve for Single-Incision Procedures
Colorectal surgeon Eric Haas, MD is the founder and president of Colorectal Surgical Associates, working closely with his colleagues, Dr. Ali Mahmood and Dr. Bartley Pickron, to offer advanced care for colorectal diseases and other conditions to the Houston area. Dr. Haas is a nationally recognized expert and innovator in laparoscopic and minimally invasive colorectal surgery

Q&A With Coronado Biosciences CEO Harlan Weisman, M.D.
It has been over a year since we last discussed Coronado Biosciences, and the company, so we thought it time for an updated Q&A on this biopharmaceutical company that continues to be one of biotech's most talked about healthcare plays.

Galapagos Increases Share Capital Through Warrant Exercises
Galapagos NV (EURONEXT BRUSSELS: GLPG)announced today a capital increase arising from employee and managementwarrant exercises.

Galapagos NV: First patients screened for Phase 2B studies with GLPG0634

Qu Biologics Appoints Former Novartis President Mr. Robert Pelzer to its Board of Directors
Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the body's immune system, is pleased to welcome Mr. Robert Pelzer to the company's Board of Directors. Mr. Pelzer was most recently President of Novartis Corporation based in New York, NY.

New Survey Results Show That the Majority of Surveyed Crohn's Patients Prefer a Monitoring Method That Does Not Involve Sedation or Radiation
Given Imaging Ltd. (NASDAQ: GIVN), a world leader in GI medical devices, and maker of PillCam® capsule endoscopy, today announced the results of Crohn's Voices, an online survey of Crohn's patients about their understanding of their condition, their approach to managing their condition with their physician, and what matters most to them in a clinical test of disease activity

Market Research Report -- Parenteral Nutrition Market Growth Driven by Rising Chronic Diseases
MarketResearch.com has announced the addition of "Parenteral Nutrition Market to 2018 - Rising Incidence of Chronic Diseases such as Cancer, AIDS and Gastrointestinal (GI) Disorders, and Increased Use of Specialty Drugs Drive Growth," to their collection of market research reports.

Cytovance(R) Biologics, Inc. Announces Manufacturing Agreement With Selexys Pharmaceuticals, Corp. for Phase II Production of SelG1
Cytovance® Biologics, Inc., a leading full-service contract manufacturer of mammalian and microbial biologics, announces an agreement with Selexys Pharmaceuticals, Corp. to produce its lead asset, the SelG1 monoclonal antibody (mAb) for a Phase II clinical study

Given Imaging Reports Data Showing Greater Role for Capsule Endoscopy in Detecting and Monitoring Crohn's Disease
Given Imaging Ltd. (NASDAQ: GIVN), a world leader in GI medical devices and pioneer of capsule endoscopy, today announced results of two studies suggesting an increased role for capsule endoscopy in detecting Crohn's lesions in the small bowel

Galapagos initiates second Phase I study with GLPG0974
Mechelen, Belgium;24 October 2012 - Galapagos NV (Euronext: GLPG) announced today that it has started its second Phase I clinical study with GLPG0974, a GPR43 inhibitor being developed to treat chronic, neutrophil-driven inflammatory conditions such as inflammatory bowel disease (IBD)

Given Imaging Announces New Studies Further Validating PillCam(R) SB as the Gold Standard for Identifying and Evaluating Small Bowel Abnormalities
Given Imaging Ltd (NASDAQ: GIVN), a world leader in GI medical devices and pioneer of capsule endoscopy, today announced new studies underscoring the value of PillCam® SB in identifying and evaluating small bowel abnormalities. The studies are being presented at the American College of Gastroenterology 2012 annual meeting taking place in Las Vegas from October 19-24, 2012

PHASE IIa LAQUINIMOD TRIAL RESULTS SHOW POSITIVE DATA FOR POTENTIAL USE IN ACTIVE CROHN'S DISEASE
Newly Presented Data at 20(th) United European Gastroenterology (UEG)Week Conference Show Significant Impact of Laquinimod on Clinical Remissionversus Placebo Jerusalem, Israel and Lund, Sweden, October 22, 2012 - TevaPharmaceuticalIndustries Ltd

Given Imaging Announces Data at UEG Week Confirms PillCam(R) SB's Role as the Diagnostic Gold-Standard for Small Bowel Diseases
Given Imaging Ltd (NASDAQ: GIVN), a world leader in GI medical devices and pioneer of capsule endoscopy, today announced the presentation of new data underscoring PillCam® SB's role as the gold standard for diagnosing small bowel diseases

Given Imaging Announces Over 80 Studies at ACG 2012 and UEG Week 2012

Dr. Ronald Herberman Joins TNI BioTech Inc. as Senior Vice President of Research and Development and Chief Medical Officer
TNI BioTech Inc (PINKSHEETS: TNIB), a public company operating in the biotech sector, announced today that Dr. Ronald Herberman joined the company as Senior Vice President of Research and Development and Chief Medical Officer effective immediately. Dr. Herberman's responsibilities include leading the company's global development, clinical research and medical initiatives.

TNI BioTech, Inc. Acquires Portfolio of Exclusive Licenses to the Portfolio of Patents of Dr. Bernard Bihari
TNI BioTech, Inc. (PINKSHEETS: TNIB) announced that it acquired exclusive licensing rights to all of the proprietary technical information, know-how, procedures, IND, protocols, methods, prototypes, designs, data and reports, which are not readily available to others through public means, and which are owned, generated or developed through experiments or testing by Dr. Bernard Bihari.

Mauna Kea Technologies Announces Record 50 Cellvizio(R) Studies Published This Year So Far
Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the endomicroscopy market and developer of Cellvizio® imaging, the fastest way to see cancer, today announced that clinicians have published more than 50 new scientific publications showing Cellvizio's clinical utility already in 2012, equal to the number of studies that were published during all of 2011

Teva to Initiate Third Phase III Trial of Oral Laquinimod for the Treatment of Relapsing Remitting Multiple Sclerosis
The clinical trial protocol has been granted a Special ProtocolAssessment agreement by the Food and Drug Administration Teva PharmaceuticalIndustries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI)provided today an update on the clinical development program of once-dailyorallaquinimod for the treatment of relapsing-remitting multiple sclerosis(RRMS)

Given Imaging Reports Second Quarter 2012 Results
Given Imaging Ltd. (NASDAQ: GIVN) today announced financial results for the second quarter ended June 30, 2012.

Active Biotech Announce That European Medicines Agency Accepts Start of Scientific Review of the Marketing Authorization Application for Laquinimod in Relapsing-Remitting Multiple Sclerosis
Active Biotech (NASDAQ OMX NORDIC: ACTI) todayannounced that the European Medicines Agency (EMA) has completed thevalidationprocess for the marketing authorization application (MAA) of the medicinalproduct laquinimod for the treatment of relapsing-remitting multiple sclerosis(RRMS).

Given Imaging Announces Reimbursement in Japan for Expanded PillCam SB(R) Indications

Houston Colon Surgeon Lectured at Annual ASCRS Meeting
At the annual scientific meeting for the American Society of Colon and Rectal Surgeons (ASCRS), Dr. Eric Haas, a colon and rectal surgeon in Houston, delivered several presentations focused on a range of laparoscopic surgical and colon cancer topics. Held on June 2-6, 2012 at the Henry B

Belly fat may serve as immunity booster
A particular kind of stomach fat previously thought to serve little purpose, may in fact play an important role in regulating the immune system, researchers say.

Why some urinary tract infections recur persistently after treatment
Scientists including one of an Indian origin have found new clues to why some urinary tract infections recur persistently after multiple rounds of treatment.

Intestinal bacteria 'may play role in inflammation'
Researchers have identified commensal bacteria in the human intestine that produce a neurotransmitter that may play a role in preventing or treating inflammatory bowel diseases such as Crohn's disease.

Effective treatments for autoimmune diseases come closer to reality
Effective treatments for autoimmune diseases may soon be possible, thanks to the development of new synthetic molecules that trick the immune system to create natural antibodies.

Geographical variation plays role in chronic digestive conditions
Geographic variation does play a role in determining occurrence of chronic digestive diseases, US researchers say.he new research points to a potential role for UV light exposure and vitamin D levels in chronic digestive conditions, Crohn's disease, which is a serious inflammatory condition in the small intestine and ulcerative colitis (UC), which similarly affects the colon.

Iron 'likely culprit behind probiotic blocker during active IBD'
A new study has found a scientific 'design' for a probiotic that could be used to treat inflammatory bowel disease (IBD), such as Crohn's disease.

29 new genetic variants linked to multiple sclerosis identified
Scientists have identified 29 new genetic variants linked to multiple sclerosis, providing key insights into the biology of a very debilitating neurological disease.

DTC genetic tests predicts inaccurate disease risks
A new study has found that direct-to-consumer (DTC) genetic tests give inaccurate predictions of disease risks and are not beneficial to individuals.

Why an apple a day can keep the doctor away
Antioxidants found in apple peels may lead to new treatments and therapies for people suffering from bowel inflammation disorders, according to a new research.

Ablynx Reports Positive Phase I Data for ALX-0061 in Rheumatoid Arthritis
GHENT, Belgium, 30 November 2011 - Ablynx [Euronext Brussels: ABLX]todayannounced positive Phase I data from the single ascending dose part of thePhaseI/II study with ALX-0061, the anti-IL-6R Nanobody, in patients withrheumatoidarthritis (RA). Based on these positive interim data, Ablynx hasinitiated amultiple ascending dose Phase II study with ALX-0061 in patients with RA

LawyersandSettlements.com Releases Its Top 10 Pharmaceutical Topics for 2011
LawyersandSettlements.com, the premier publication for Online Legal Media, today released its list of the hottest consumer-related pharmaceutical legal news stories for its readership during the last year.

Healthy and Strong - Equity Research on Osiris Therapeutics, Inc. and Biogen Idec Inc.
Today, www.WorldStreetFundamentals.com released its industry report highlighting Osiris Therapeutics, Inc. (NASDAQ: OSIR) and Biogen Idec Inc. (NASDAQ: BIIB). Full fundamental and technical analysis is available at www.WorldStreetFundamentals.com/Reports.php.

Is It Really Your Fault That You're Fat?
As Americans, we represent the fattest nation on the planet, and it's killing us.

Comment on this story

Share